CT骨骼肌质量与危重症患者短期和长期死亡率的关联:系统评价与Meta分析
该系统评价与Meta分析遵循PRISMA 2020指南,纳入35项研究共9366例ICU成人患者,多数为回顾性单中心研究,覆盖脓毒症、COVID-19和创伤等异质性人群。骨骼肌质量最常以第三腰椎骨骼肌指数报告,低骨骼肌面积和指数与短期死亡率(OR=2.33,95%CI 1.90-2.87,I²=41.39%)和长期死亡率(OR=2.67,95%CI 1.45-4.92,I²=62.24%)升高显著相关。低肌肉质量总体患病率为42%(95%CI 34-49%,I²=98.2%)。作者认为CT评估的骨骼肌质量可能作为危重症患者的预后标志物,并强调需要标准化测量和定义方案以提高研究间可比性。
要点
- ICU入院时腰椎水平CT评估的低骨骼肌面积和指数与短期死亡风险升高相关(OR=2.33,95%CI 1.90-2.87,I²=41.39%)。
- 低骨骼肌面积和指数与长期死亡风险升高相关(OR=2.67,95%CI 1.45-4.92,I²=62.24%)。
- 危重症患者中低肌肉质量总体患病率为42%(95%CI 34-49%,I²=98.2%)。
- 骨骼肌质量最常以第三腰椎骨骼肌指数报告,短期死亡率主要在28天或30天评估,长期死亡率在90天、6个月和1年评估。
- 作者认为CT评估的骨骼肌质量可能作为危重症患者的预后标志物,并强调需要标准化测量和定义方案。
适用人群与场景
- 纳入标准:≥18岁、入住ICU的危重成人,且在ICU入院±7天内测量了腰椎水平CT骨骼肌质量。
- 纳入研究人群包括脓毒症、COVID-19和创伤等异质性患者,样本量36至939例,年龄范围40至70余岁,男性占62%。
研究设计与关键结果
- 系统评价与Meta分析,遵循PRISMA 2020指南,检索MEDLINE和Embase无日期限制,最终纳入35项研究共9366例参与者。
- 多数为回顾性单中心研究,来自四大洲,使用JBI队列研究清单进行质量评估。
- 低骨骼肌面积和指数与短期死亡率升高显著相关(OR=2.33,95%CI 1.90-2.87,I²=41.39%)。
- 低骨骼肌面积和指数与长期死亡率升高显著相关(OR=2.67,95%CI 1.45-4.92,I²=62.24%)。
- 低肌肉质量总体患病率为42%(95%CI 34-49%,I²=98.2%)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入35项研究。
- 局限性:多数为回顾性单中心研究,人群异质性大,低肌肉质量定义和测量方案不统一;短期死亡率Meta分析异质性I²=41.39%,长期死亡率Meta分析异质性I²=62.24%,患病率Meta分析异质性I²=98.2%。
- 作者指出需要标准化测量和定义低骨骼肌质量的方案以提高研究间可比性。
对床旁实践的改变
- 作者认为ICU入院时腰椎水平CT评估的骨骼肌质量可能作为危重症患者的预后标志物。
- 作者指出需要标准化测量和定义低骨骼肌质量的方案以改善研究间可比性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Low skeletal mass, often present at hospital admission, has been associated with poor prognoses.
AIM: To explore the association between computed tomography (CT)-derived skeletal muscle mass at the lumbar level and short- and long-term mortality in critically ill patients.
METHODS: Following PRISMA 2020 guidelines, we included studies on critically ill adults (≥ 18 years) hospitalized in intensive care units (ICU) that measured CT-derived skeletal muscle mass at the lumbar vertebral level within ± 7 days of ICU admission. The primary outcome was mortality, categorized as short-term (including ICU, hospital, 28- and 30-day mortality) and long-term (> 30 days) mortality. MEDLINE and Embase databases were searched without date restrictions. Study screening was performed using Rayyan, data extraction was guided by a custom-designed tool, and quality assessment was performed using the JBI Cohort Study Checklist. A meta-analysis was conducted, focusing on studies that reported short- and long-term mortality among patients with preserved and reduced skeletal muscle. A prevalence meta-analysis was also performed for studies that reported the size of subgroups with low muscle mass.
RESULTS: Out of 1248 unique records, 35 studies met the inclusion criteria, involving 9366 participants. The majority were retrospective, single-centre studies conducted on four continents and included heterogeneous populations such as patients with sepsis, COVID-19 and trauma. Sample sizes ranged from 36 to 939, with a wide age range, from 40 to 70 s, and a predominance of male patients (62%). Skeletal mass was most commonly reported as skeletal muscle index at the third lumbar vertebra. Studies reported mainly short-term mortality on day 28 or 30. Long-term mortality, measured at 90 days, 6 months, and 1 year, was evaluated in 11 studies. Meta-analyses revealed that low skeletal muscle mass area and index were significantly associated with increased risks of both short (OR = 2.33, CI 1.90-2.87, I2 = 41.39%)-and long-term mortality (OR = 2.67, CI 1.45-4.92, I2 = 62.24%). The overall prevalence of low muscle mass was 42% (CI 34-49%, I2 = 98.2%).
CONCLUSIONS: CT-assessed skeletal muscle mass at the lumbar level on admission to ICU is associated with both short- and long-term mortality. It may serve as a prognostic marker in critically ill patients. Standardized protocols for measuring and defining low skeletal muscle mass in this population are essential to improve comparability across studies.
参考来源
- Bertoni Maluf VA, Herrmann FR, Platon A, et al. Exploring the association between computed tomography (CT)-derived skeletal muscle mass and short- and long-term mortality in critically ill patients: a systematic review and meta-analysis. Crit Care. 2025. PMID: 40462133. doi:10.1186/s13054-025-05427-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。